09:18 AM EDT, 05/08/2025 (MT Newswires) -- Ligand Pharmaceuticals ( LGND ) reported Q1 core adjusted net income Thursday of $1.33 per diluted share, up from $1.20 a year earlier.

Analysts polled by FactSet expected $1.21.

Revenue for the quarter ended March 31 was $45.3 million, up from $31 million a year earlier.

Analysts surveyed by FactSet expected $38.7 million.

The company said it continues to expect 2025 adjusted diluted EPS between $6.00 and $6.25 on revenue of $180 million to $200 million.

Analysts polled by FactSet expect full-year adjusted EPS of $6.11 and revenue of $190.9 million.

Shares were 0.9% higher in recent premarket activity.